$SSKN
STRATA Skin Sciences, Inc. Stock $sskn

$sskn Overview Financials Valuation SEC Filings Company Website

2015 Q1 Form 10-K Financial Statement

#000161577415000575 Filed on March 30, 2015

Income Statement

Concept	2015 Q1	2014 Q4	2014
Revenue	$80.00K	$370.0K	$915.0K
YoY Change	-18.06%	164.29%	70.71%
Cost Of Revenue	$710.0K	$1.180M	$4.935M
YoY Change	-22.7%	-1280.0%	13.68%
Gross Profit	-$630.0K	-$810.0K	-$4.020M
YoY Change	-23.25%	-437.5%	5.65%
Gross Profit Margin	-787.5%	-218.92%	-439.34%
Selling, General & Admin	$2.760M	$2.610M	$10.96M
YoY Change	-13.75%	-15.81%	-29.45%
% of Gross Profit
Research & Development	$240.0K	$220.0K	$1.641M
YoY Change	-66.09%	-59.26%	-56.61%
% of Gross Profit
Depreciation & Amortization	$320.0K	$420.0K	$1.785M
YoY Change	-54.29%	-35.38%	-26.66%
% of Gross Profit
Operating Expenses	$3.000M	$2.830M	$12.60M
YoY Change	-23.3%	-22.25%	-38.01%
Operating Profit	-$3.630M	-$3.640M	-$16.62M
YoY Change	-23.29%	7.06%	-31.13%
Interest Expense	-$3.660M	-$890.0K	$2.380M
YoY Change	-305354.38%	323.81%	321.99%
% of Operating Profit
Other Income/Expense, Net	$20.00K	$20.00K	$2.477M
YoY Change	-100.62%	100.0%	-236.55%
Pretax Income	-$7.270M	-$4.500M	-$14.15M
YoY Change	-8.9%	-2.39%	-45.47%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$7.270M	-$4.500M	-$14.15M
YoY Change	-8.9%	-2.39%	-45.49%
Net Earnings / Revenue	-9087.5%	-1216.22%	-1545.9%
Basic Earnings Per Share
Diluted Earnings Per Share	-$5.636M	-$3.846M	-$13.35M
COMMON SHARES
Basic Shares Outstanding	7.525M shares	6.037M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q1	2014 Q4	2014
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.230M	$11.43M	$11.43M
YoY Change	1.35%	202.38%	202.38%
Cash & Equivalents	$8.230M	$11.43M	$11.43M
Short-Term Investments
Other Short-Term Assets	$450.0K	$270.0K	$270.0K
YoY Change	-4.26%	-69.32%	-69.32%
Inventory	$5.190M	$5.275M	$5.280M
Prepaid Expenses
Receivables	$10.00K	$220.0K	$220.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$13.88M	$17.20M	$17.20M
YoY Change	-2.73%	66.2%	66.18%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.620M	$1.961M	$1.960M
YoY Change	-45.91%	-46.87%	-46.88%
Goodwill
YoY Change
Intangibles		$37.00K
YoY Change		-11.9%
Long-Term Investments
YoY Change
Other Assets	$690.0K	$48.00K	$870.0K
YoY Change	1337.5%	0.0%	1640.0%
Total Long-Term Assets	$2.340M	$2.867M	$2.870M
YoY Change	-24.12%	-24.17%	-24.07%
TOTAL ASSETS
Total Short-Term Assets	$13.88M	$17.20M	$17.20M
Total Long-Term Assets	$2.340M	$2.867M	$2.870M
Total Assets	$16.22M	$20.07M	$20.07M
YoY Change	-6.53%	42.02%	42.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.320M	$1.240M	$1.190M
YoY Change	0.67%	-16.16%	-19.59%
Accrued Expenses	$650.0K	$842.0K	$960.0K
YoY Change	-20.72%	-0.24%	14.29%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.880M	$2.686M	$2.190M
YoY Change	-64.27%	-52.48%	-61.24%
LONG-TERM LIABILITIES
Long-Term Debt	$4.710M	$5.000M	$5.000M
YoY Change
Other Long-Term Liabilities	$90.00K	$610.0K	$610.0K
YoY Change	-35.71%	238.89%	238.89%
Total Long-Term Liabilities	$4.800M	$5.108M	$5.610M
YoY Change	3354.6%	2676.09%	3016.67%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.880M	$2.686M	$2.190M
Total Long-Term Liabilities	$4.800M	$5.108M	$5.610M
Total Liabilities	$8.680M	$7.794M	$7.790M
YoY Change	-21.08%	33.55%	33.39%
SHAREHOLDERS EQUITY
Retained Earnings		-$182.3M
YoY Change		8.41%
Common Stock		$194.6M
YoY Change		10.27%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$7.540M	$12.28M	$12.28M
YoY Change
Total Liabilities & Shareholders Equity	$16.22M	$20.07M	$20.07M
YoY Change	-6.53%	42.02%	42.04%

Cashflow Statement

Concept	2015 Q1	2014 Q4	2014
OPERATING ACTIVITIES
Net Income	-$7.270M	-$4.500M	-$14.15M
YoY Change	-8.9%	-2.39%	-45.49%
Depreciation, Depletion And Amortization	$320.0K	$420.0K	$1.785M
YoY Change	-54.29%	-35.38%	-26.66%
Cash From Operating Activities	-$3.200M	-$3.040M	-$17.71M
YoY Change	-55.06%	-22.05%	-8.76%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$20.00K
YoY Change
Cash From Investing Activities	$0.00	$0.00	$20.00K
YoY Change		-100.0%	-100.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$11.46M
YoY Change			-45.89%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	10.00K	25.34M
YoY Change	-100.0%	-99.81%	23.49%
NET CHANGE
Cash From Operating Activities	-3.200M	-3.040M	-17.71M
Cash From Investing Activities	0.000	0.000	20.00K
Cash From Financing Activities	0.000	10.00K	25.34M
Net Change In Cash	-3.200M	-3.030M	7.650M
YoY Change	-173.73%	-361.21%	-287.5%
FREE CASH FLOW
Cash From Operating Activities	-$3.200M	-$3.040M	-$17.71M
Capital Expenditures	$0.00	$0.00	$0.00
Free Cash Flow	-$3.200M	-$3.040M	-$17.71M
YoY Change	-55.06%	-15.08%	-28.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014	dei	Document Type DocumentType	10-K
CY2014	dei	Amendment Flag AmendmentFlag	false
CY2014	dei	Document Period End Date DocumentPeriodEndDate	2014-12-31
CY2014	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2014	dei	Entity Registrant Name EntityRegistrantName	MELA SCIENCES, INC. /NY
CY2014	dei	Entity Central Index Key EntityCentralIndexKey	0001051514
CY2014	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2013Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	64000	USD
CY2014	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2014	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2014	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2014	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2014Q2	dei	Entity Public Float EntityPublicFloat	16544970	USD
CY2014	dei	Trading Symbol TradingSymbol	MELA
CY2015Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	7525146	shares
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11434000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3783000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	220000	USD
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	57000	USD
CY2014	us-gaap	Sales Revenue Net SalesRevenueNet	915000	USD
CY2013	us-gaap	Sales Revenue Net SalesRevenueNet	536000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	5275000	USD
CY2013Q4	us-gaap	Inventory Net InventoryNet	5631000	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	274000	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	880000	USD
CY2014	us-gaap	Cost Of Revenue CostOfRevenue	4935000	USD
CY2013	us-gaap	Cost Of Revenue CostOfRevenue	4341000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	17203000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	10351000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1961000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3691000	USD
CY2014Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	37000	USD
CY2013Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	42000	USD
CY2014	us-gaap	Gross Profit GrossProfit	-4020000	USD
CY2013	us-gaap	Gross Profit GrossProfit	-3805000	USD
CY2014Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	821000	USD
CY2013Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	0	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	48000	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	48000	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1641000	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3782000	USD
CY2014Q4	us-gaap	Assets Assets	20070000	USD
CY2013Q4	us-gaap	Assets Assets	14132000	USD
CY2014	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	10961000	USD
CY2013	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	15536000	USD
CY2014	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2013	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	1011000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1240000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1479000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	842000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	844000	USD
CY2014	us-gaap	Operating Expenses OperatingExpenses	12602000	USD
CY2013	us-gaap	Operating Expenses OperatingExpenses	20329000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	43000	USD
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	244000	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-16622000	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-24134000	USD
CY2014Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	499000	USD
CY2013Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	3017000	USD
CY2014Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	62000	USD
CY2013Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	68000	USD
CY2014	us-gaap	Investment Income Interest InvestmentIncomeInterest	8000	USD
CY2013	us-gaap	Investment Income Interest InvestmentIncomeInterest	8000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2686000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5652000	USD
CY2014	us-gaap	Interest Expense InterestExpense	2380000	USD
CY2013	us-gaap	Interest Expense InterestExpense	564000	USD
CY2014Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	80000	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	5000	USD
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	27000	USD
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2013Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	48000	USD
CY2014	mela	Write Off Of Unamortized Loan Costs WriteOffOfUnamortizedLoanCosts	0	USD
CY2013	mela	Write Off Of Unamortized Loan Costs WriteOffOfUnamortizedLoanCosts	983000	USD
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	1000	USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	6000	USD
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.10
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.10
CY2013Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	120000	USD
CY2014	us-gaap	Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	8103000	USD
CY2013	us-gaap	Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-296000	USD
CY2014Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	5108000	USD
CY2013Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	184000	USD
CY2014Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	5001000	USD
CY2013Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	0	USD
CY2014Q4	us-gaap	Liabilities Liabilities	7794000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	5836000	USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	194562000	USD
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	176439000	USD
CY2014	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	16000	USD
CY2013	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-182293000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-168148000	USD
CY2014	mela	Registration Rights Liquidating Damages RegistrationRightsLiquidatingDamages	3420000	USD
CY2013	mela	Registration Rights Liquidating Damages RegistrationRightsLiquidatingDamages	0	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	12276000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	8296000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	20070000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14132000	USD
CY2014	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	150000	USD
CY2013	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	21000	USD
CY2014	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2477000	USD
CY2013	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1814000	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-14145000	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-25948000	USD
CY2014	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5295929	shares
CY2013	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	4289450	shares
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	95000	USD
CY2013Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	46000	USD
CY2014Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1409000	USD
CY2013Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	325000	USD
CY2014Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	74000	USD
CY2013Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	33000	USD
CY2014Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	USD
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	11787	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	11787	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	21174000	USD
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6037232	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6037232	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4750160	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4750160	shares
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	13975000	USD
CY2013	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	15725000	USD
CY2013	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	18000	USD
CY2013	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	652000	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1301000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	413000	USD
CY2014	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1790000	USD
CY2013	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2439000	USD
CY2014	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	USD
CY2013	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	1011000	USD
CY2014	mela	Bad Debt Expense BadDebtExpense	52000	USD
CY2013	mela	Bad Debt Expense BadDebtExpense	46000	USD
CY2014	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	0	USD
CY2013	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	41000	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	413000	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	1301000	USD
CY2014	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	191000	USD
CY2013	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	250000	USD
CY2014	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1943000	USD
CY2013	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
CY2014	mela	Provision For Inventory Reserve ProvisionForInventoryReserve	1084000	USD
CY2013	mela	Provision For Inventory Reserve ProvisionForInventoryReserve	325000	USD
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	215000	USD
CY2013	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-77000	USD
CY2014	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	784000	USD
CY2013	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-121000	USD
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-606000	USD
CY2013	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-86000	USD
CY2014	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	USD
CY2013	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-36000	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-241000	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-484000	USD
CY2014	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-6000	USD
CY2013	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	27000	USD
CY2014	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-40000	USD
CY2013	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-24000	USD
CY2014	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-238000	USD
CY2013	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	4000	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-17709000	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-19413000	USD
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5188000	USD
CY2014	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	17000	USD
CY2013	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	0	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	17000	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-5188000	USD
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	11458000	USD
CY2014	us-gaap	Open Tax Year OpenTaxYear	2009
CY2013Q4	mela	Aggregate Consideration Receivable For Warrants To Be Issued AggregateConsiderationReceivableForWarrantsToBeIssued	685715	shares
CY2014	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt	15000000	USD
CY2013	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	USD
CY2014	mela	Liquid Investments Maturity Period To Be Classified As Cash Equivalent Maximum LiquidInvestmentsMaturityPeriodToBeClassifiedAsCashEquivalentMaximum	Three months or less
CY2013	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt	6000000	USD
CY2014	us-gaap	Repayments Of Debt RepaymentsOfDebt	0	USD
CY2013	us-gaap	Repayments Of Debt RepaymentsOfDebt	6425000	USD
CY2014	mela	Payments Fo Rborrowings And Warrant Exercises PaymentsFoRborrowingsAndWarrantExercises	103000	USD
CY2014	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2013	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	18000	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	25343000	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	20522000	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	7651000	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-4079000	USD
CY2014	us-gaap	Interest Paid InterestPaid	116000	USD
CY2013	us-gaap	Interest Paid InterestPaid	0	USD
CY2014	mela	Amount Reclassified From Warrant Liability To Equity AmountReclassifiedFromWarrantLiabilityToEquity	0	USD
CY2013	mela	Amount Reclassified From Warrant Liability To Equity AmountReclassifiedFromWarrantLiabilityToEquity	652000	USD
CY2014	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	12300000	USD
CY2013	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2014	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	5788000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7862000	USD
CY2014	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="center"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"><b>1. Principal Business Activities</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><b><i>Organization and Business</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"><b> </b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 48.95pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">MELA Sciences, Inc., a Delaware corporation (the “Company”), is a medical device company dedicated to designing and developing innovative software-driven technology for the early detection and prevention of skin cancer. The Company is focused on the commercialization of its flagship product, the MelaFind<sup style="font-style:normal">®</sup> System, or MelaFind, as well as the further design and development of this technology. MelaFind is a non-invasive, point-of-care (in the doctor’s office) instrument to aid in the detection of melanoma. The system features a hand-held component that emits light of multiple wavelengths to capture digital data from clinically atypical pigmented skin lesions. The data are then analyzed utilizing sophisticated classification algorithms, “trained” by our proprietary database of melanomas and benign lesions. This result provides information to assist in the management of the patient’s disease, including information useful in the decision of whether to biopsy the lesion.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 48.95pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">MelaFind’s components include:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 6.1pt"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 18pt"> <div style="CLEAR:both;CLEAR: both">•</div> </td> <td> <div style="CLEAR:both;CLEAR: both">a <i>hand-held imager</i>, which employs high precision optics and multi-spectral illumination (multiple wavelengths of light);</div> </td> </tr> </table> <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 6.1pt"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 18.35pt"> <div style="CLEAR:both;CLEAR: both">•</div> </td> <td> <div style="CLEAR:both;CLEAR: both">a <i>proprietary database</i> of pigmented skin lesions, believed to be the largest prospective database to date in the U.S.; and</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -18.35pt; MARGIN: 0px 0px 0px 24.45pt; FONT: 10pt Times New Roman, Times, Serif"> </div> <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 6.1pt"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 18pt"> <div style="CLEAR:both;CLEAR: both">•</div> </td> <td> <div style="CLEAR:both;CLEAR: both"><i>lesion classifiers</i>, which are sophisticated mathematical algorithms that extract lesion feature information and classify lesions.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 48.95pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 48.95pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">In November 2011, the Company received a Pre-Market Approval, or PMA, from the U.S. Food and Drug Administration (“FDA”) for MelaFind, having already received Conformité Européenne (“CE”) Mark approval in September 2011. On March 7, 2012, the Company installed the first commercial MelaFind System. The Company initially marketed the MelaFind System primarily to aesthetic dermatologists through a lease program in which users paid an upfront placement fee and periodic fees for use. In 2013, because the launch objectives were not realized, the Company reviewed its marketing strategy. Revenues amounting to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">536</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">278</font> in 2013 and 2012, respectively, did not meet expectations, and due to the nature of the lease agreements the Company continued to record high cost of sales. The Company implemented a significant cost reduction program in 2013 that affected all areas of its business, and which continued throughout 2014. As a result of this strategy review in 2013, the Company undertook several steps that it believes will significantly improve MelaFind’s commercial acceptance by: 1) changing its business model from solely a rental-based model to include a capital sales option; 2) refocusing its marketing efforts on medical dermatology, and particularly those dermatologists who treat patients at high risk for melanoma; and 3) beginning the process of obtaining a coverage determination from the Centers for Medicare & Medicaid Services (“CMS”), the federal agency that administers Medicare, in order to obtain reimbursement by Medicare and ultimately by private insurers for the use of MelaFind. During 2014 the Company made significant strides in each of these areas, although it anticipates that it will require a few years of continued effort before the success of this strategy can be assessed. The Company anticipates that the insurance reimbursement process could take several years to complete. <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 49.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 49.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">In July 2014, the Company announced that it took the first step in the process of obtaining insurance reimbursement for its Multi-Spectral Digital Skin Lesion Analysis (“MSDSLA”) procedure that is performed by dermatologists utilizing the MelaFind system as an aid in the detection of melanoma. The Company submitted an application for a CPT code, which is necessary for Medicare Part B reimbursement by the CMS. On March 9, 2015, the February 2015 CPT<sup style="font-style:normal">®</sup> Editorial Summary of Panel Actions was posted to the website of the American Medical Association (the “AMA”). The CPT Editorial Panel accepted the addition of Category III codes 039XX1T and 039XX2T to report MSDSLA of atypical cutaneous lesions, which applies to the MelaFind System. Barring any further action by the Panel, the Company expects that these codes will be posted to the AMA CPT website by July 1, 2015 with an effective date of January 1, 2016 and will provide the basis for pursuing third party and CMS insurance coverage for MelaFind. The Company plans to commence efforts to obtain reimbursement from private insurers, which could take several years to complete.</div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 49.5pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 49.5pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">Until the Company obtains insurance reimbursement from the CMS and private insurers, it expects that revenues will not be sufficient to cover operating and other expenses. The Company’s financial success will depend on a number of factors, primary among which is the ability to sell MelaFind systems, increase the penetration with dermatologists, encourage the usage of these systems, and control costs. Currently, the Company cannot determine when it will have sufficient revenues to cover continuing developmental costs, manufacturing, marketing and other operational expenses.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2012	us-gaap	Sales Revenue Net SalesRevenueNet	278000	USD
CY2014Q1	mela	Net Proceeds From Issuance Of Common Stock And Warrant NetProceedsFromIssuanceOfCommonStockAndWarrant	11458000	USD
CY2014Q3	mela	Proceeds From Sale Of Convertible Preferred Stock Common Stock And Warrants ProceedsFromSaleOfConvertiblePreferredStockCommonStockAndWarrants	15000000	USD
CY2014	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 48.95pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>Use of Estimates</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 48.95pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could materially differ from those estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q3	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	15000000	USD
CY2014Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	12925000	USD
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	24211541	shares
CY2013	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1525918	shares
CY2014	mela	Associated Revenue Over Related Service Period AssociatedRevenueOverRelatedServicePeriod	Generally expected to be two years
CY2014	us-gaap	Income Tax Examination Likelihood Of Unfavorable Settlement IncomeTaxExaminationLikelihoodOfUnfavorableSettlement	Greater than fifty percent
CY2014	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2014	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	0	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7153000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9094000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5192000	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5403000	USD
CY2014	us-gaap	Depreciation Depreciation	1785000	USD
CY2013	us-gaap	Depreciation Depreciation	2434000	USD
CY2014	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	445000	USD
CY2013	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	509000	USD
CY2014	mela	Noncancellable Operating Leases Term Of Expiration NoncancellableOperatingLeasesTermOfExpiration	2016-12
CY2013Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	27794000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	478000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	477000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	955000	USD
CY2013	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	136000	USD
CY2013	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.03	pure
CY2014	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0165	pure
CY2013	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0175	pure
CY2014Q4	us-gaap	Fair Value Assumptions Exercise Price FairValueAssumptionsExercisePrice	1.20
CY2013Q4	us-gaap	Fair Value Assumptions Exercise Price FairValueAssumptionsExercisePrice	6.40
CY2013	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.9343	pure
CY2013	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P5Y3M29D
CY2014	mela	Fair Value Assumptions Treasury Yield Period FairValueAssumptionsTreasuryYieldPeriod	P5Y
CY2014Q3	mela	Fair Value Of Warrant Obligation FairValueOfWarrantObligation	5296000	USD
CY2014Q3	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	4566000	USD
CY2014Q3	mela	Fair Value Of Warrants Issued FairValueOfWarrantsIssued	491000	USD
CY2014Q3	us-gaap	Senior Long Term Notes SeniorLongTermNotes	4647000	USD
CY2013Q1	mela	Fair Value Of Warrant Obligation FairValueOfWarrantObligation	563000	USD
CY2013Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	5300000	USD
CY2013Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	983000	USD
CY2014Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	499000	USD
CY2013Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	3017000	USD
CY2014	us-gaap	Royalty Revenue RoyaltyRevenue	149000	USD
CY2013	us-gaap	Royalty Revenue RoyaltyRevenue	20000	USD
CY2013Q3	us-gaap	Defined Benefit Plan Special Termination Benefits DefinedBenefitPlanSpecialTerminationBenefits	100000	USD
CY2014	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-4270000	USD
CY2013	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-8822000	USD
CY2014	us-gaap	Income Tax Reconciliation Tax Settlements State And Local IncomeTaxReconciliationTaxSettlementsStateAndLocal	-217000	USD
CY2013	us-gaap	Income Tax Reconciliation Tax Settlements State And Local IncomeTaxReconciliationTaxSettlementsStateAndLocal	-1557000	USD
CY2014	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4487000	USD
CY2013	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	10379000	USD
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2014	us-gaap	Convertible Preferred Stock Converted To Other Securities ConvertiblePreferredStockConvertedToOtherSecurities	1887000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	57367000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	35086000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Other DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther	3840000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Other DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther	3681000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	71048000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	66561000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	71048000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	66561000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2013Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34	pure
CY2014Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	144759000	USD
CY2014	mela	Unrecognized Tax Benefits Recognition Description UnrecognizedTaxBenefitsRecognitionDescription	Tax positions that meet the more likely than not threshold are measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate finalization with the taxing authority.
CY2013	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	206000	USD
CY2014Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	13078920	shares
CY2014Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1293000	USD
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.74	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.83	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.72	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.77	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0190	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0245	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0071	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0245	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	242654	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	29000	USD
CY2014Q4	mela	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Non Vested ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNonVested	1207459	shares
CY2014	mela	Share Based Compensation Requisite Service Period Yet To Be Recognized Value ShareBasedCompensationRequisiteServicePeriodYetToBeRecognizedValue	901000	USD
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	499447	shares
CY2013	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1806	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	433679	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	306616	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1308835	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1205162	shares
CY2014	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	202943	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	40.10
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	14.60
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.70
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	10.00
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	27.70
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	16.74
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	16.20
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.76
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	101376	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	13.45
CY2014Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	USD
CY2013	mela	Weighted Average Remaining Contractual Term In Years Granted WeightedAverageRemainingContractualTermInYearsGranted	P9Y6M
CY2014	mela	Weighted Average Remaining Contractual Term In Years Granted WeightedAverageRemainingContractualTermInYearsGranted	P9Y4M24D
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y4M24D
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y9M18D
CY2013	mela	Common Stock And Warrants Issued In Private Placementvalue CommonStockAndWarrantsIssuedInPrivatePlacementvalue	2573000	USD
CY2014	mela	Warrants Issued In Private Placementvalue WarrantsIssuedInPrivatePlacementvalue	-5585000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	10353000	USD
CY2014	mela	Redemption Of Convertible Preferred Stock In Connection With Private Plcaementvalue RedemptionOfConvertiblePreferredStockInConnectionWithPrivatePlcaementvalue	1000	USD
CY2014	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2014	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	1589000	USD
CY2014	mela	Exercise Of Warrntsvalue ExerciseOfWarrntsvalue	0	USD
CY2014	mela	Series Preferred Stock And Warrants Issued In Private Placementvalue SeriesPreferredStockAndWarrantsIssuedInPrivatePlacementvalue	11458000	USD
CY2014Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	539000	USD
CY2014Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1329731	shares
CY2014	mela	Conversion Of Convertible Preferred Stock Into Common Stock ConversionOfConvertiblePreferredStockIntoCommonStock	513000	USD
CY2013	mela	Conversion Of Convertible Preferred Stock Into Common Stock ConversionOfConvertiblePreferredStockIntoCommonStock	0	USD
CY2014	mela	Conversion Of Senior Secured Convertible Debentures Into Common Stock ConversionOfSeniorSecuredConvertibleDebenturesIntoCommonStock	1589000	USD
CY2013	mela	Conversion Of Senior Secured Convertible Debentures Into Common Stock ConversionOfSeniorSecuredConvertibleDebenturesIntoCommonStock	0	USD
CY2014	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	4565000	USD
CY2013	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	0	USD
CY2013	mela	Reclassification Of Property And Equipment To Inventory ReclassificationOfPropertyAndEquipmentToInventory	5402000	USD
CY2013	us-gaap	Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions	18000	USD
CY2014Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	1308835	shares
CY2014	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit	1.31
CY2014	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit	68.90
CY2014Q4	mela	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number Vested ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberVested	101376	shares
CY2013Q4	mela	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number Vested ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberVested	126183	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	25.60
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.22
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.00
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	17000	USD
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	90000	shares
CY2013Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	90000	shares
CY2013Q2	mela	Additional Stock Based Compensation Expenses AdditionalStockBasedCompensationExpenses	423000	USD
CY2014	mela	Share Based Compensation Arrangement By Share Based Payment Award Award Expiration Period Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriodMaximum	P10Y
CY2014	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P4Y
CY2013	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P4Y
CY2014	mela	Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period For Directors ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriodForDirectors	P1Y
CY2013	mela	Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period For Directors ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriodForDirectors	P1Y
CY2014	mela	Lapsing Of Restrictions Related To Restricted Stock Issued Start Date LapsingOfRestrictionsRelatedToRestrictedStockIssuedStartDate	2013-04-25
CY2014Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	8410000	USD
CY2014	mela	Issuance Cost Of Common Stock And Warrants IssuanceCostOfCommonStockAndWarrants	992000	USD
CY2014Q4	us-gaap	Inventory Gross InventoryGross	6684000	USD
CY2013Q4	us-gaap	Inventory Gross InventoryGross	5956000	USD
CY2014Q4	mela	Working Capital WorkingCapital	14517000	USD
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	USD
CY2014Q4	us-gaap	Derivative Fair Value Of Derivative Liability Amount Not Offset Against Collateral DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral	233000	USD
CY2013Q4	us-gaap	Derivative Fair Value Of Derivative Liability Amount Not Offset Against Collateral DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral	3017000	USD
CY2014	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2784000	USD
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.03
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-6.05
CY2014Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	689000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	0	USD
CY2014Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	785000	USD
CY2013Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	135000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	0	USD
CY2014Q3	mela	Convertible Preferred Stock Initial Conversion Price ConvertiblePreferredStockInitialConversionPrice	2.565
CY2014	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	1887000	USD
CY2013	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	0	USD
CY2014	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16032000	USD
CY2013	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-25948000	USD
CY2014Q4	us-gaap	Interest Expense Debt InterestExpenseDebt	1200000	USD
CY2014Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	The reverse split took effect at the start of trading on July10, 2014 on a 1-for-10 split basis.
CY2014	mela	Series B Convertible Preferred Stock Issued In Private Placement Value SeriesBConvertiblePreferredStockIssuedInPrivatePlacementValue	1000	USD
CY2014	mela	Payment Of Long Term Debt Expense PaymentOfLongTermDebtExpense	1012000	USD
CY2013	mela	Payment Of Long Term Debt Expense PaymentOfLongTermDebtExpense	245000	USD
CY2014Q4	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1589000	USD
CY2014Q4	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	619490	shares
CY2013Q4	mela	Aggregate Intrinsic Value Exercised AggregateIntrinsicValueExercised	17000	USD
CY2013Q4	mela	Aggregate Intrinsic Value For Forfeited Or Expired AggregateIntrinsicValueForForfeitedOrExpired	27000	USD
CY2013Q4	mela	Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Intrinsic Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedIntrinsicValue	0	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	103000	USD
CY2014	mela	Increase In Additional Paid In Capital Convertible Debt With Conversion Feature IncreaseInAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	0	USD
CY2014	mela	Decrease In Additional Paid In Capital Convertible Debt With Conversion Feature DecreaseInAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	0	USD
CY2014Q4	mela	Deferred Tax Assets Warrant Liablity DeferredTaxAssetsWarrantLiablity	3123000	USD
CY2013Q4	mela	Deferred Tax Assets Warrant Liablity DeferredTaxAssetsWarrantLiablity	0	USD
CY2014Q3	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	5847955	shares
CY2013	mela	Payments Fo Rborrowings And Warrant Exercises PaymentsFoRborrowingsAndWarrantExercises	0	USD
CY2014	mela	Reclassification Of Property And Equipment To Inventory ReclassificationOfPropertyAndEquipmentToInventory	0	USD

Files In Submission

Name	View Source	Status
0001615774-15-000575-index-headers.html	Edgar Link	pending
0001615774-15-000575-index.html	Edgar Link	pending
0001615774-15-000575.txt	Edgar Link	pending
0001615774-15-000575-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
mela-20141231.xml	Edgar Link	completed
mela-20141231.xsd	Edgar Link	pending
mela-20141231_cal.xml	Edgar Link	unprocessable
mela-20141231_def.xml	Edgar Link	unprocessable
mela-20141231_lab.xml	Edgar Link	unprocessable
mela-20141231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
s100850_10k.htm	Edgar Link	pending
s100850_ex10-3.htm	Edgar Link	pending
s100850_ex10-4.htm	Edgar Link	pending
s100850_ex23-1.htm	Edgar Link	pending
s100850_ex31-1.htm	Edgar Link	pending
s100850_ex31-2.htm	Edgar Link	pending
s100850_ex32-1.htm	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SSKN
STRATA Skin Sciences, Inc. Stock $sskn

2015 Q1 Form 10-K Financial Statement

#000161577415000575 Filed on March 30, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SSKN STRATA Skin Sciences, Inc. Stock $sskn

2015 Q1 Form 10-K Financial Statement

#000161577415000575 Filed on March 30, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SSKN
STRATA Skin Sciences, Inc. Stock $sskn